{
  "prompt": {
    "guidelineId": "cg1195-anti-d-guideline-pdf",
    "fieldsProcessed": [
      "humanFriendlyName",
      "organisation",
      "yearProduced",
      "summary"
    ],
    "enhancedFields": 4,
    "contentLength": 3490
  },
  "response": "{\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Guidelines for Anti-D Administration in RhD-Negative Pregnant Women\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"RCOG\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text provided does not contain a publication year. If you have another guideline text that includes the year, please share it, and I can extract the 4-digit year for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Guideline on Anti-D Administration for RhD-Negative Pregnant Women:** - **Purpose:** Prevent RhD sensitization and Haemolytic Disease of the Fetus and Newborn (HDFN) via targeted Anti-D administration. - **Testing:** Cell-free DNA fetal D testing identifies RhD-positive fetuses, allowing selective Anti-D prophylaxis. - **Administration:** Anti-D (1500IU) should be given within 72 hours of sensitizing events (e.g., delivery, bleeding, procedures) or as routine prophylaxis if cfDNA testing is declined/failed. - **Documentation:** Record on electronic prescription charts and Maternity Information System; monitor for allergic reactions. - **Special Cases:** IV/subcutaneous Anti-D for severe thrombocytopenia/bleeding disorders. - **Birth Management:** Cord blood/Kleihauer testing post-delivery; additional Anti-D if fetal-maternal hemorrhage (FMH) >4mL. - **Follow-Up:** Missed doses require DATIX reporting, SHOT notification, and antibody testing at 6 months postpartum. - **Monitoring:** Deviations tracked via DATIX and Patient Blood Management Committee. **Pathways:** - **Pathway 1:** cfDNA testing with consent. - **Pathway 2:** Routine Anti-D prophylaxis if cfDNA testing is unsuccessful or fetus is D-positive. **Key Points:** Universal precautions for blood products, strict timing for Anti-D, and structured follow-up for sensitization risks\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "endpoint": "enhanceGuidelineMetadata",
  "timestamp": "2025-06-18T22-02-26",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"guidelineId\": \"cg1195-anti-d-guideline-pdf\",\n  \"fieldsProcessed\": [\n    \"humanFriendlyName\",\n    \"organisation\",\n    \"yearProduced\",\n    \"summary\"\n  ],\n  \"enhancedFields\": 4,\n  \"contentLength\": 3490\n}\n\nA: {\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Guidelines for Anti-D Administration in RhD-Negative Pregnant Women\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"RCOG\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text provided does not contain a publication year. If you have another guideline text that includes the year, please share it, and I can extract the 4-digit year for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Guideline on Anti-D Administration for RhD-Negative Pregnant Women:** - **Purpose:** Prevent RhD sensitization and Haemolytic Disease of the Fetus and Newborn (HDFN) via targeted Anti-D administration. - **Testing:** Cell-free DNA fetal D testing identifies RhD-positive fetuses, allowing selective Anti-D prophylaxis. - **Administration:** Anti-D (1500IU) should be given within 72 hours of sensitizing events (e.g., delivery, bleeding, procedures) or as routine prophylaxis if cfDNA testing is declined/failed. - **Documentation:** Record on electronic prescription charts and Maternity Information System; monitor for allergic reactions. - **Special Cases:** IV/subcutaneous Anti-D for severe thrombocytopenia/bleeding disorders. - **Birth Management:** Cord blood/Kleihauer testing post-delivery; additional Anti-D if fetal-maternal hemorrhage (FMH) >4mL. - **Follow-Up:** Missed doses require DATIX reporting, SHOT notification, and antibody testing at 6 months postpartum. - **Monitoring:** Deviations tracked via DATIX and Patient Blood Management Committee. **Pathways:** - **Pathway 1:** cfDNA testing with consent. - **Pathway 2:** Routine Anti-D prophylaxis if cfDNA testing is unsuccessful or fetus is D-positive. **Key Points:** Universal precautions for blood products, strict timing for Anti-D, and structured follow-up for sensitization risks\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": null
}